Before joining EXUMA, Dr. Frost led the Health Sector of Intrexon Corporation, where he was responsible for expanding their oncology franchise and gene and cellular-based therapies for a number of orphan diseases. Previously, he was the CEO and member of the Board of Directors at Halozyme Therapeutics. Dr. Frost earned his B.A. in biochemistry and molecular biology from the UC, Santa Cruz, his Ph.D. in the Department of Pathology at the UC, San Francisco, and postdoctoral research at the Sidney Kimmel Cancer Center.